Keytruda: An Overview of This Immunotherapy Drug

Keytruda, also known by its generic name pembrolizumab, is a groundbreaking immunotherapy medication that has revolutionized.


Keytruda: An Overview of This Immunotherapy Drug

Keytruda, also known by its generic name pembrolizumab, is a groundbreaking immunotherapy medication that has revolutionized the treatment landscape for various types of cancer. As a targeted therapy, it works differently from traditional chemotherapy by harnessing the body's own immune system to fight cancer cells.

What is Keytruda (Pembrolizumab)?

Keytruda is a monoclonal antibody that falls into a class of drugs called PD-1 (Programmed Death-1) inhibitors. It is an important tool in modern oncology, approved for treating a wide range of solid tumors and blood cancers. Unlike treatments that directly attack cancer cells, Keytruda helps the immune system recognize and destroy them more effectively.

How Does Keytruda Work?

Cancer cells often develop ways to evade the immune system. One common mechanism is by expressing a protein called PD-L1 (Programmed Death-Ligand 1) on their surface. This protein can bind to the PD-1 receptor found on T-cells (a type of immune cell), essentially putting the T-cell to sleep and preventing it from attacking the cancer.

Keytruda works by blocking the interaction between PD-1 on T-cells and PD-L1 on cancer cells. By doing so, it "releases the brakes" on the immune system, allowing T-cells to become active again and mount an effective anti-tumor response. This mechanism is crucial for reactivating the body's natural defenses against cancer.

Approved Uses of Keytruda

Keytruda has received approval for treating numerous types of cancer, often after initial treatments have failed or as a first-line therapy in specific cases. Some of the cancers for which Keytruda is approved include:


  • Melanoma (skin cancer)

  • Non-small cell lung cancer (NSCLC)

  • Small cell lung cancer (SCLC)

  • Head and neck squamous cell carcinoma (HNSCC)

  • Classical Hodgkin lymphoma (cHL)

  • Primary mediastinal large B-cell lymphoma (PMBCL)

  • Urothelial carcinoma (bladder cancer)

  • Renal cell carcinoma (kidney cancer)

  • Colorectal cancer (with specific genetic markers)

  • Gastric and gastroesophageal junction adenocarcinoma

  • Esophageal carcinoma

  • Cervical cancer

  • Hepatocellular carcinoma (liver cancer)

  • Triple-negative breast cancer (TNBC)

  • Endometrial carcinoma

  • And others, including certain tumors with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR)

The specific indication and eligibility for Keytruda depend on various factors, including the type and stage of cancer, previous treatments, and the presence of certain biomarkers.

Administration and Dosage

Keytruda is administered intravenously (IV infusion) by a healthcare professional, typically over a period of about 30 minutes. The dosage and frequency of administration vary depending on the specific cancer being treated, the patient's weight, and their response to the medication. It is usually given every three or six weeks.

Treatment with Keytruda continues as long as the patient benefits from it and does not experience unacceptable side effects.

Potential Side Effects of Keytruda

While Keytruda can be highly effective, like all medications, it can cause side effects. These often result from the activated immune system attacking healthy cells as well as cancer cells, a phenomenon known as "immune-mediated side effects."

Common Side Effects:


  • Fatigue

  • Nausea

  • Diarrhea or constipation

  • Rash and itching

  • Decreased appetite

  • Joint pain

  • Cough

Serious Immune-Mediated Side Effects:

These can affect almost any organ and require immediate medical attention. They include inflammation of:


  • Lungs (pneumonitis)

  • Colon (colitis)

  • Liver (hepatitis)

  • Hormone glands (thyroid, pituitary, adrenal, pancreas leading to diabetes)

  • Kidneys (nephritis)

  • Skin (severe skin reactions)

  • Nervous system (neuropathy, myasthenia gravis)

Patients are closely monitored for these side effects throughout their treatment and for several months afterward. It is crucial for patients to report any new or worsening symptoms to their doctor immediately.

Important Considerations

Before starting Keytruda, patients should inform their healthcare provider about all their medical conditions, including autoimmune diseases, organ transplant history, and current medications. This helps the medical team determine if Keytruda is appropriate and to manage potential risks.

Keytruda is a powerful medication, and its use requires careful consideration and management by experienced oncologists. It is not suitable for everyone, and the decision to use it is made after a thorough evaluation of the patient's individual circumstances.

Disclaimer: This article provides general information about Keytruda (pembrolizumab) and is intended for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment. Do not disregard professional medical advice or delay in seeking it because of something you have read in this article.